Overview of tacrolimus-based immunosuppression after heart or lung transplantation

This publication has 52 references indexed in Scilit:

• Efficacy and safety of tacrolimus (TAC) vs. cyclosporine microemulsion (CME) in de novo cardiac transplant recipients: 6-month results
  The Journal of Heart and Lung Transplantation, 2003
• Prospective randomized international multi-center investigator driven study comparing TAC and CSA (+MMF/steroids) after lung transplantation - interim analysis of 110 patients
  The Journal of Heart and Lung Transplantation, 2003
• Long term follow-up of a prospective randomized trial comparing tacrolimus versus cyclosporine in combination with MMF after lung transplantation
  The Journal of Heart and Lung Transplantation, 2003
• Tacrolimus/mycophenolate mofetil vs cyclosporine/mycophenolate mofetil: impact on infections following cardiac transplantation
  The Journal of Heart and Lung Transplantation, 2002
• Tacrolimus and Sirolimus: a new therapeutic approach for immunosuppression after heart transplantation
  The Journal of Heart and Lung Transplantation, 2002
• Tacrolimus excels cyclosporine a in prevention of cardiac allograft vasculopathy - a prospective IVUS, angiography and Doppler study
  The Journal of Heart and Lung Transplantation, 2002
• Conversion from cyclosporin A to tacrolimus is safe and decreases blood pressure, cholesterol levels and TGF-β1 type I receptor expression
  Clinical Transplantation, 2001
• MONITORING OF SOLUBLE HLA ALLOANTIGENS AND ANTI-HLA ANTIBODIES IDENTIFIES HEART ALLOGRAFT RECIPIENTS AT RISK OF TRANSPLANT-ASSOCIATED CORONARY ARTERY DISEASE1
  Transplantation, 1996
• FK506 augments activation-induced programmed cell death of T lymphocytes in vivo.
  Journal of Clinical Investigation, 1995
• Tacrolimus
  Drugs, 1993